Sabinsa intends to market the product under the name OcuFors.
Sabinsa (East Windsor, NJ) has received a patent in Japan for a Coleus forskolii–derived natural product targeting glaucoma treatmet. Specifically, the product is a water-soluble form of naturally available diterpenes derived from Coleus forskolii. Sabinsa intends to market the product under the name OcuFors.
“The patent covers both the method for solubilizing diterpenes using randomly methylated beta-cyclodextrin molecules and applications thereof in glaucoma,” the company described in a press release.
It said that compared to the glaucoma drug Timolol, which it described as “a non-selective beta blocker,” OcuFors has been shown to be superior for treating open-angle glaucoma and reducing intraocular pressure.
The company said it is seeking OcuFors’ approval as a glaucoma drug in several other countries, and that OcuFors is the first naturally derived pharmaceutical product that has been approved by the Drug Controller General of India.
Driving Sustainability in Nutraceuticals: How Ingredient Brands Are Raising the Bar
April 26th 2024Health-minded consumers, especially Generation Z, value nutraceutical companies with sustainability embedded into their corporate philosophy—from product development to packaging. This article discusses how responsible companies are responding to the consumer call for greater sustainability by implementing environmentally friendly manufacturing practices that ultimately lead to waste reduction, improved supplier communications and lower supply chain risk. Those who have taken steps to demonstrate a genuine commitment to sustainability are standing out with improved outcomes for all.
The Nutritional Outlook Podcast Episode 29: 2024 Ingredients to Watch
January 31st 2024Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.